Connect with us

Published

on

Shares of the Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on its first day of trading on Wall Street.

The newly listed Nasdaq stock opened up 40% before pulling back some.

The German biotech’s initial public offering was priced Thursday night at $15 per share, the high end of the expected range. The company, which aims to make psychedelic drugs to treat mental health disorders, raised $225 million at a valuation of $2.3 billion.

Atai is the third psychedelic biotech to go public in the U.S., following in the footsteps of MindMed, which went public on the Nasdaq in April, and Founders Fund-backed Compass Pathways, which listed in September. As of Thursday’s close, Compass Pathways was up 26% since its debut, and MindMed, which just announced its CEO’s resignation, was down about 19% since its IPO.

Each biotech is developing therapies using the psychedelic mushroom compound psilocybin, LSD, and MDMA derivatives to treat addiction and mental illnesses such as depression, anxiety, schizophrenia and traumatic brain injury. Three years after its founding, Atai Life Sciences has 10 therapeutic programs in its pipeline, each at various stages of clinical trials.

Atai founder and Chairman Christian Angermayer said on CNBC’s “Squawk Box” on Friday, “The world we’re building is a bad place for our brain, so mental health issues will go up. But I do think we have some real shots in our portfolio to end the mental health crisis.”

Investor interest in psychedelic treatments has grown alongside burgeoning interest in these therapies from the medical community.

Johns Hopkins University, Yale University, the University of California, Berkeley, and the Icahn School of Medicine are among the centers studying psychedelics and psychology. Recent studies establishing MDMA’s promise in treating post-traumatic stress disorder and the efficacy of psilocybin, a hallucinogenic chemical found in psychedelic mushrooms, in treating drug-resistant depression have only heightened interest in the space.

Angermayer was an early investor in Compass Pathways, and his own company Atai serves as a holding company for various psychedelic start-ups pursuing alternative treatments for mental illness. He told CNBC on Friday that new-age biotechs are building on centuries of practice in shamanistic cultures and religions.

There are currently federal restrictions for psychedelic mushrooms, MDMA — commonly known as molly or ecstasy — and LSD around the world. However, Oregon last year became the first U.S. state to legalize psychedelics for therapeutic use. Residents in Washington, D.C., also recently voted in support of decriminalizing the use of psychedelics for medicinal purposes.

Atai Life Sciences at the Nasdaq for its IPO, June 18, 2021.
Source: Nasdaq

Angermayer is betting that federal approval of these drugs for therapeutic use could make a huge difference for those suffering from mental illness. “They are very, very powerful medications, but they have to be taken under supervision. … You will be tripping while you are sitting with your therapist.”

Atai Life Sciences is backed by the billionaire investor Thiel, as well as Mike Novogratz’s Galaxy Investments and Angermayer’s own Apeiron Investment Group, among others.

According to venture capital tracker CB Insights, VC deals in psychedelics have risen substantially in the last three years: 2018 and 2019 saw less than $100 million of venture capital invested in psychedelic start-ups, but 2020 saw $346 million. By April 2021, VCs had already invested $329 million in the industry.

It’s no wonder that Atai’s was more than 12 times oversubscribed, according to one market source who asked to remain anonymous due to the nature of the discussion. “A good portion was taken up by existing investors,” the person said, adding that Thiel is the largest existing investor and that he’s “doubled down” in the IPO.

Investment fund Palo Santo said it had taken a notable stake in Atai’s IPO. “There is an urgent need to address our broken mental healthcare system,” Daniel Goldberg, co-founder of Palo Santo, said in a statement. “We believe psychedelics will expand treatment options and transform the outdated system.”

Atai submitted an S-1 filing to the Securities and Exchange Commission in April that showed it raised an aggregate of $362.3 million from private investors at that point.

The company, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.

Atai, which has roughly 50 staff members in offices across Berlin, New York and San Diego, is currently partnered with 14 companies focusing on drug development and other technologies.

In exchange for a majority stake in the drugs and technologies they’re developing, Atai helps the scientists raise money, work with regulators and conduct clinical trials. None of Atai’s drugs have been formally approved by regulators to date.

Thiel made an $11.9 million investment in Atai through his venture firm, Thiel Capital, in November.

“Atai’s great virtue is to take mental illness as seriously as we should have been taking all illness all along,” Thiel, who co-founded Palantir and PayPal, said in a statement shared with CNBC at the time. “The company’s most valuable asset is its sense of urgency.”

Continue Reading

Technology

Reddit shares soar 14% after company reports revenue pop in debut earnings report

Published

on

By

Reddit shares soar 14% after company reports revenue pop in debut earnings report

Reddit CEO Steve Huffman hugs mascot Snoo as Reddit begins trading on the New York Stock Exchange (NYSE) in New York on March 21, 2024. 

Timothy A. Clary | AFP | Getty Images

Reddit shares rallied 14% in extended trading on Tuesday after the company released quarterly results for the first time since its IPO in March.

Here’s how the company did:

  • Loss per share: $8.19 loss per share. That may not compare with the $8.71 loss expected by LSEG
  • Revenue: $243 million vs. $212.8 million expected by LSEG

Revenue climbed 48% from $163.7 million a year earlier. The company reported $222.7 million in ad revenue for the period, up 39% year over year, which is a faster rate of growth than at its top competitors.

Digital advertising companies have started growing again at a healthy clip after brands reeled in spending to cope with inflation in 2022. Meta‘s ad revenue jumped 27% in the first quarter, followed by 24% growth at Amazon and 13% growth at Google parent Alphabet.

Reddit reported a net loss of $575.1 million. Stock-based compensation expenses and related taxes were $595.5 million, primarily driven by IPO charges.

For the second quarter, Reddit expects revenue of $240 million to $255 million, topping the $224 million expected by analysts, according to LSEG. The midpoint of the guidance range suggests growth of about 32% for the second quarter, up from $183 million from a year earlier.

Reddit, which hosts millions of online forums on its platform, was founded in 2005 by Alexis Ohanian and Steve Huffman, the company’s CEO. 

“We see this as the beginning of a new chapter as we work towards building the next generation of Reddit,” Huffman said in a release Tuesday.

Reddit began trading under the ticker symbol “RDDT” on the New York Stock Exchange in March. The company priced its IPO at $34 per share, which valued the company around $6.5 billion. When tech valuations were red hot in 2021, Reddit’s private market valuation reached $10 billion.

The stock climbed past $58 in after-hours trading on Tuesday before coming back a bit. Should the stock close above $57.75 on Wednesday, it would be at its highest since March 26, its fourth day of trading. The shares closed that day at $65.11, their highest yet.

The company reported 82.7 million daily active users for its first quarter, up from the 76.6 million expected by StreetAccount. Average revenue per user worldwide rose 8% to $2.94 from $2.72 a year ago.

Reddit will hold its first quarterly call with investors at 5 p.m. ET.

WATCH: Reddit shares climb after earnings

Reddit shares climb on revenue beat in first quarterly report since IPO

Continue Reading

Technology

Tesla Chairwoman Robyn Denholm has sold over $50 million worth of stock in 2024

Published

on

By

Tesla Chairwoman Robyn Denholm has sold over  million worth of stock in 2024

Robyn Denholm, chairman of Tesla Inc., speaks during an American Chamber of Commerce in Australia event in Sydney, Australia, on Wednesday, March 27, 2019.

Brendon Thorne | Bloomberg | Getty Images

Tesla Chairwoman Robyn Denholm has just sold $17.3 million worth of her shares in the electric vehicle maker, according to a filing Monday, bringing her total stock sales this year to more than $50 million.

Denholm, who joined Tesla’s board as an independent director in 2014 and became chair four years later, sold the shares as part of what’s called a 10b5-1 program put into place in October. She has now sold all of the 281,116 shares allowed in the agreement.

While Denholm still has the vast majority of the 1.66 million shares she owned as of the end of last year, according to the company’s proxy filing, her stock sales follow hefty selling from other big stakeholders. Former Tesla Senior Vice President Drew Baglino, who announced his resignation in mid-April, sold shares worth around $181.5 million soon after his departure, according to a filing.

Another Tesla board member, Kathleen Wilson-Thompson, set up a 10b5-1 trading plan in February 2024, for the potential sale of up to 280,000 shares by or before Feb. 28, 2025.

Tesla shares are down 26% this year, closing Monday at $184.76. The slide comes as the company faces increased competition, weakened demand for its EVs and a drop in first-quarter deliveries.

CEO Elon Musk has tried to focus investors’ attention on the company’s self-driving future instead of its core automotive business. He told investors on Tesla’s earnings call last month that those who doubt the company’s ability to deliver self-driving vehicles should stay away from the stock. For years, Tesla has been working to develop, but hasn’t brought to market, software that will make its existing cars autonomous, a dedicated robotaxi and humanoid robots capable of factory work.

“If somebody doesn’t believe Tesla’s going to solve autonomy, I think they should not be an investor in the company,” Musk said on the call.

In Denholm’s early years on the Tesla board, she served on the audit committee. She eventually replaced Musk as chair in November 2018, after the company struck an agreement with the SEC to settle civil securities fraud charges requiring Musk to relinquish that role temporarily, among other provisions.

The SEC had charged Musk and Tesla with securities fraud after Musk said, in a series of tweets in 2018 that he was considering taking the company private at $420 per share with “funding secured.” The tweets led to a stretch of volatility in Tesla shares.

Before joining the Tesla board, Denholm served in executive roles at Sun Microsystems, and in finance roles at Toyota in Australia and at accounting firm Arthur Andersen. Denholm is currently part of Tesla’s audit, compensation, nominating and corporate governance, and disclosure controls committees.

Denholm, who didn’t respond to a request for comment, is a named defendant in a shareholder lawsuit — Tornetta vs. Musk — that was decided in January. The judge in the Delaware case ruled that Tesla’s 2018 CEO pay plan, which was the largest in public corporate history, was only allowed by a board that was “beholden to Musk,” and should be rescinded.

In her opinion, Chancellor Kathaleen McCormick wrote that by serving on Tesla’s board, Denholm received “life-changing” compensation, which “far exceeded the compensation she received from other sources.”

Tesla's big gamble: Full Self-Driving in the wild

Denholm’s latest stock sales coincide with struggles at Tesla and a broad restructuring effort that’s included thousands of layoffs.

Demand for Tesla’s EVs slumped in the first quarter, and inventory levels have visibly swelled. Revenue in the period fell 9% from a year earlier, the steepest drop since 2012, while net income plunged 55%.

Musk said in an internal memo in April that Tesla was cutting more than 10% of its global headcount. He didn’t say which departments or locations would be most affected. In the earnings call, he referred to the restructuring as a “pruning exercise” and added, “We’re not giving up anything that is significant that I’m aware of.” He said that if the company organizationally is “5% wrong per year,” its cumulative inefficiency comes out to 25% or 30%.

Denholm and Musk are currently trying to convince shareholders to vote with directors and executives at Tesla on a number of proxy proposals.

The most material proposal asks shareholders to return to Musk his compensation package that was invalidated by the Delaware Chancery Court in the Tornetta decision. The pay package would be worth tens of billions of dollars in Tesla shares to Musk.

Tesla’s largest individual retail shareholder, tech billionaire Leo Koguan, has repeatedly called for investors to vote against the plan. In a post on X, Koguan recently wrote, “Don’t be a sucker, just vote NO.”

Don’t miss these exclusives from CNBC PRO

Recent Tesla announcements and leaks have created opportunities for peers, says former Ford CEO

Continue Reading

Technology

Food startup Hungryroot uses AI to reduce waste, a major climate offender

Published

on

By

Food startup Hungryroot uses AI to reduce waste, a major climate offender

Food startup uses AI to cut food waste

Food waste is so prolific in the U.S. that roughly one-third of the amount produced ends up in landfills rather than in stomachs. That adds up to excess production, packaging, storage and delivery requirements, all negatively contributing to climate change.

A recent study published in the journal Science found that food production accounts for 26% of global greenhouse gas emissions.

Food delivery services like HelloFresh, Blue Apron and EveryPlate reduce that somewhat by sending consumers what they need for specific recipes.

A New York-based startup called Hungryroot is going one step further. The 9-year-old company — using artificial intelligence — is providing a more curated experience and delivering the precise amount of food a consumer will use.

Customers answer a slew of questions about their food likes and dislikes, allergies and health goals. They also answer questions on how and when they cook. Taking those answers, Hungryroot’s technology infers what recipes and grocery items are best for each customer.

“Hungryroot is entirely designed to give you just the foods that you’re going to need for your week,” Ben McKean, the company’s CEO, told CNBC. “And it gives you simple recipes, so you know exactly what to do with them, and as a result, food waste with our customers is significantly reduced.”

Hungryroot sends users a list of what’s in their weekly cart, allowing them to approve or change items.

The company can reduce its own waste as well. If it determines that a user has no preference between broccoli and Brussels sprouts, and the company happens to have more broccoli in its warehouse, that’s what they’ll recommend.

The company said these processes help lead to 80% less food waste at its facilities compared with a traditional supermarket.

Investors say the unique model is also good for its bottom line.

“They have been profitable for three or four years now, which is unusual for a lot of these e-commerce, food businesses,” said Jeremy Liew, a partner at Lightspeed Venture Partners. “They’ve been able to drive that through efficiency of spend, and because they have built a business that customers really love.”

In addition to Lightspeed, Hungryroot is backed by L Catterton, Crosslink Capital, KarpReilly and Lerer Hippeau. The company has raised a total of $75 million.

 — CNBC climate producer Lisa Rizzolo contributed to this piece.

Don’t miss these exclusives from CNBC PRO

Continue Reading

Trending